Very Low Doses of Thalidomide as Single Agent in Relapsed/Refractory Multiple Myeloma

Publisher： Karger

E-ISSN： 1421-9662|116|1|70-71

ISSN： 0001-5792

Source： Acta Haematologica, Vol.116, Iss.1, 2006-07, pp. : 70-71

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 2, 2018-02 ,pp. : 179-186

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 3, 2015-08 ,pp. : 336-348

John Wiley & Sons Inc

Access to resources Recommend Favorite

Fatal Cytomegalovirus Pneumonia and Associated Herpes Virus Infection in a Relapsed/Refractory Multiple Myeloma Patient Treated with Bortezomib plus Dexamethasone

By  

Case Reports in Oncology, Vol. 2, Iss. 2, 2009-07 ,pp. : 140-143

Karger

Access to resources Recommend Favorite

Real‐world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 269-4727, Iss. 1, 2013-02 ,pp. : 41-47

John Wiley & Sons Inc

Access to resources Recommend Favorite

Real‐world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 38, Iss. 1, 2013-02 ,pp. : 41-47

John Wiley & Sons Inc

Access to resources Recommend Favorite